Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
E. Briggs (Birmingham(West Midlands), United Kingdom), G. Burge (Birmingham(West Midlands), United Kingdom), H. Alldrick (Birmingham(West Midlands), United Kingdom), M. Bellamy (Birmingham(West Midlands), United Kingdom), S. Burge (Birmingham(West Midlands), United Kingdom), G. Walters (Birmingham(West Midlands), United Kingdom). What influences patient choice of antifibrotic treatment in IPF?. 590

Member's Comments

No comment yet.

Related content which might interest you: A rejuvenation effect of the antifibrotic therapy correlates with lung function improvement in IPF patients Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 What patients with IPF can expect concerning symptoms and quality of life during first six months of antifibrotic treatment? Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Results of antifibrotic drugs in the treatment of idiopathic pulmonary fibrosis. A real life study. Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Impact of compliance and specialist nurse support on IPF survival in patients commenced on antifibrotic therapy Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Efficacy of switching antifibrotic therapy in idiopathic pulmonary fibrosis: real life data Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Effect of sildenafil add-on to antifibrotic treatment in IPF patients Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Can different approaches to anti-inflammatory therapy result in different outcomes in cystic fibrosis patients? Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007 Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy? Source: Eur Respir J 2004; 24: 1-2 Year: 2004 Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma? Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001 New antifibrotic drugs: will interstitial diseases patients still need lung transplantation? Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs Year: 2020 Next generation of anti-inflammatory therapy for COPD? Source: Eur Respir J, 50 (4) 1702084; 10.1183/13993003.02084-2017 Year: 2017 Comment on: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 57 (3) 2004645; 10.1183/13993003.04645-2020 Year: 2021 Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019 Year: 2020